Kyyak S, Blatt S, Schiegnitz E, Heimes D, Staedt H, Thiem DGE, Sagheb K, Al-Nawas B, Kämmerer PW. Front Bioeng Biotechnol. 2021 Feb 17;9:599224.

https://pubmed.ncbi.nlm.nih.gov/33681155/

The goal of the study was to evaluate the effect of four differently processed bovine bone substitute materials on the viability, metabolic activity of human osteoblasts as well as on the expression of genes crucial for bone mineralization. In addition, the effect of iPRF on all parameters was assessed.

Methods:

Human osteoblasts were cultured with one of the following bone grafting materials, either in the presence or absence of iPRF: cerabone®, Bio-Oss®, Creos Xenogain®, MinerOss® X. Cell viability and metabolic activity were assessed using immunofluorescence microscopy and MTT assay respectively. Expression of bone gene markers alkaline phosphatase, bone morphogenetic protein 2, and osteonectin was examined using real time PCR. Parameters were evaluated at 3, 7 and 10 days following incubation.

Results:

• Highest cell viability in the cerabone® group
• Addition of iPRF increased cell viability in all groups with the highest values for cerabone® at 3 and 7 days
• Highest cellular metabolic activity in the cerabone® + iPRF group among the evaluated bone grafting materials
• No overall significant differences in gene marker expression among the evaluated bone grafting materials

Summary/Conclusions:

• Significantly increased viability of human osteoblasts by cerabone®
• Higher osteoblastic biological activities for cerabone® compared to non-sintered bovine bone grafts
• Addition of iPRF resulted in significantly increased biological activities
• Results suggest that high temperature treatment of cerabone® is beneficial for osteoblast activation

Clinical significance:

cerabone®:

• shows optimal biocompatibility for bone forming cells
• stimulates osteoblast activation and proliferation essential for new bone formation
• promotes expression of osteoblastic genes important for bone mineralization